Urologix, Inc. (ULGX)
-OTC Markets 0.31 
0.01(3.13%) 3:33PM EDT
| Prev Close: | 0.32 |
|---|
| Open: | 0.30 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.50 |
|---|
| Beta: | -0.11 |
|---|
| Next Earnings Date: | 19-Aug-13 |
|---|
| Day's Range: | 0.27 - 0.33 |
|---|
| 52wk Range: | 0.25 - 1.00 |
|---|
| Volume: | 77,500 |
|---|
| Avg Vol (3m): | 46,291 |
|---|
| Market Cap: | 6.45M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- UROLOGIX INC FinancialsEDGAR Online Financials(Tue, Jun 11)
- Urologix to Transfer From NASDAQ to the OTCQB MarketplaceGlobeNewswire(Wed, Jun 5)
- UROLOGIX INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TranEDGAR Online(Wed, Jun 5)
- UROLOGIX INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TranEDGAR Online(Thu, May 23)
- UROLOGIX INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 2)
- Urologix's CEO Discusses F3Q 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- Urologix's CEO Discusses F3Q 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- Urologix, Inc. Earnings Call scheduled for 5:00 pm ET todayCCBN(Wed, May 1)
- Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual GuidanceGlobeNewswire(Wed, May 1)
- Q3 2013 Urologix, Inc. Earnings Release - After Market CloseCCBN(Wed, May 1)
- Urologix to Host Its Fiscal Year 2013 Third Quarter Conference CallBusiness Wire(Thu, Apr 25)
- UROLOGIX INC Files SEC form 8-K, Other EventsEDGAR Online(Wed, Apr 17)
- Urologix Receives Extension From NASDAQ to Regain Compliance With Listing RequirementsGlobeNewswire(Wed, Apr 17)
- Urologix announces milestone in Prositiva RF therapy licensing agreementtheflyonthewall.com(Mon, Apr 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 0.39 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.21 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | -0.32 |
|---|
Business Summary
Urologix, Inc. engages in the development, manufacture, and marketing of non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement, benign prostatic hyperplasia (BPH).
View More